FIGURE 3 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
Year: 2023
Type: other
Abstract: Pharmacodynamics of palbociclib and fulvestrant. A–D, In each panel, the y-axis represents the ratio of the G1-to-S transition rate treated by palbociclib/fulvestrant to the G1-to-S transition rate in control (zero drug concentration) and the x-axis represents drug concentrations in the unit of nmol/L. The gray shaded area corresponds to the 95% credible interval of the posterior predictive values. A, Fulvestrant only in −DOX cells. B, Palbociclib only in −DOX cells. C, Fulvestrant only in +DOX cells. D, Palbociclib only in +DOX cells. E and F are the surface plots for G1–S TR50 (z-axis) with respect to the combinations of palbociclib (x-axis) and fulvestrant (y-axis). E, For −DOX cells: because the response to fulvestrant is extremely sensitive, the unit is rescaled to 1e−6 nmol/L; palbocilib is in the unit of nmol/L. F, For +DOX cells: the units of palbociclib and fulvestrant are both in nmol/L.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4388735362